Carol Davila University of Medicine and Pharmacy, Bucharest, Romania b
|
|
- Grant Calvin Shelton
- 6 years ago
- Views:
Transcription
1 Mædica - a Journal of Clinical Medicine MAEDICA a Journal of Clinical Medicine 2015; 10(3): ORIGINAL PAPERS Improving Melanoma Path Reports: the Importance of Histopathological Parameters in Diagnosis of Cutaneous Melanoma Alina Mariana AVRAM a ; Olga Dana SIMIONESCU b,c ; Mariana COSTACHE d ; Mariana GRIGORE c a Carol Davila University of Medicine and Pharmacy, Bucharest, Romania b Department of Dermatology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania c Department of Dermatology, Colentina Clinical Hospital, Bucharest, Romania d Department of Pathology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania ABSTRACT Background: Despite the fact that melanoma is an easy approachable tumor for diagnosis, the incidence of this skin cancer is still increasing. Histopathological assessment of melanocytic tumors is the gold standard in melanoma diagnosis and represents a problematic aspect of dermatology and pathology. Over the past decades many efforts have been made in determining histological characteristics influencing the prognosis and survival of patients with clinically localized primary melanoma. Some of these parameters also proved to be essential for tumor staging and choosing adequate clinical management. Objective: We present a retrospective study of 21 melanoma cases with histopathological errors or incomplete path reports, with the intention to raise awareness about the importance of an accurate diagnosis for the management of these cases and for patient prognosis. Methods: We retrospectively reviewed data from pathology reports and discharge medical records from 21 patients diagnosed with melanoma between 2006 and 2014 and treated in other hospitals that presented in our clinic for second opinion. All slides were reviewed by an authorized dermatopathologist and the new path report was compared with the other ones, presented by the patients. Results: The majority of the path reports were incomplete, with absent (35.7%) or wrong (35.7%) tumor thickness, making impossible to stage the tumor. Absence of histopathological diagnosis was noticed in 3 cases and a wrong diagnosis was determined in 3 patients. Other missing parameters were ulceration status, mitotic rate, microsatellitosis and surgical margins evaluation. missing or incorrect determined in half of the cases. Conclusions: This study presents the fact that there is a lack of relevant information in the path reports of melanoma cases, making impossible to stage and treat this patients, with adverse clinical impact. We want to emphasize the importance of a standardized histopathological evaluation of melanocytic tumors, consistent with the generally accepted standards, leading to improved healthcare quality and reduced medico legal risks associated with melanoma. Address for correspondence: Alina Avram, Carol Davila University of Medicine and Pharmacy, 8 Eroilor Sanitari Avenue, , Bucharest, Romania. alina_2705@yahoo.com Article received on the 12 th of May Article accepted on the 23 rd of September Maedica A Journal of Clinical Medicine, Volume 10 No
2 Increased attention to the essential elements for the diagnosis and treatment of melanoma can improve the care of most of these patients and improve prognosis and survival rates. Keywords: melanoma, path report, error, prognostic factor, Breslow index INTRODUCTION The poor prognosis and limited treatment options for advanced cutaneous melanoma highlights the importance of early and correct diagnosis in order to increase quality of patient care and survival rates (1-4). Improving histopathological diagnosis accuracy in identification of melanomas is an ongoing effort. Many histological parameters have been described, with impact on patient prognosis and are currently introduced in every guideline for the diagnosis and treatment of melanoma (5-8). Recommended pathology data sets that include these parameters are currently included in many evidence-based protocols for the examination of melanoma specimens (9,10). In 2013, a comparison of the most important protocols, developed by the Royal College of Pathologists of Australasia, Royal College of Pathologists (United Kingdom) and College of American Pathologists, showed that some of these histological parameters are recommended but some are considered required (11,12). According to these guidelines diagnosis, macroscopic description of the tumor, Breslow thickness, ulceration status, mitotic rate, microsatellites, surgical margin involvement and AJCC/TNM staging are mandatory (10,13). Tumor thickness is the most important prognostic factor in primary localized melanoma, reported by Breslow since 1970 (14). Patients with thin melanoma, < 1 mm tumor thickness, have a very good prognosis, with 5-year survival rate over 90%, while for Breslow index > 4 mm, the rates decrease to 50 % (4,15). It represents a principal T stage parameter, essential for tumor staging and has replaced the Clark level of invasion in terms of patients outcome prediction (16). Surgical excision margins recommended in all guidelines for the diagnosis and treatment of melanoma are currently established according to the tumor thickness (7,17). It is a potentially relevant predictor of sentinel lymph node (SLN) metastasis in both thin and thick invasive cutaneous melanomas (18). Depending on the value of this parameter, clinicians can decide whether to recommend the sentinel lymph node biopsy to a patient. SLNB is indicated for values between 1 and 4 mm, but also for patients with melanoma of 0,76-1 mm associated with young age, high mitotic rate and ulceration (19-21). The mitotic rate is the second most powerful prognostic factor that replaced the Clark level of invasion for T1 staging in the 7th edition of American Joint Committee on Cancer (AJCC) Melanoma Staging, implemented in 2010 (22-25). The presence of tumor ulceration is associated with lower survival rates and a high risk of developing metastasis (9,26). Other histological parameters recommended to be included in the path reports are: Clark level of invasion (I-V), regression (present/absent), angiolymphatic invasion (present/absent/ indeterminate), lymphocytic infiltrate (absent/ present brisk/present non-brisk), radial versus vertical growth phase, perineural invasion (present/absent/indeterminate) (10). MATERIAL AND METHODS We conducted a retrospective study of 21 melanoma cases, diagnosed with different types of cutaneous melanoma and treated in other hospitals or private practices between 2006 and These patients pre sented in our clinic for second opinion and the incomplete or wrong path report made the therapeutic approach very difficult. The slides were reviewed by an authorized dermatopathologist and a complete path report, with all 13 histologic parameters recommended by the international protocols, was issued for each case. Findings were compared with the first path report, presented by patient. We evaluated variables such as histopathological subtypes, Breslow depth, mitotic rate, ulceration status, Clark level, peritumoral and intratumoral lymphocytic inflammatory infiltrate, perineural and angiolymphatic invasion, regression, microscopic satellitosis and surgical margins. Clinical variables were obtained from the patient s medical records. A written informed consent was signed by every patient, allowing us to use the data for research purposes. Maedica A Journal of Clinical Medicine, Volume 10 No
3 Gender Male Female Total Age range no no no TABLE 1. Distribution of the patients by age range and gender. Histological subtype Frequency % SSM Nodular Acral lentiginous LMM Total TABLE 2. Distribution of subtypes of primary cutaneous melanoma. Path report error Number of patients Absence of histopathologic exam 3 Wrong diagnosis 3 Incomplete reports 14 Delayed diagnosis 1 Second opinion not indicated 17 TABLE 3. Path report categories. RESULTS The study sample included 21 melanoma cases; 62% were women and 38%, men. The mean age was years. The mean age of women was lower than that of men, and years, respectively. The age ranged from 25 to 93 years. There was a peak of incidence for those aged between 35 and 55 years (Table1). The histological subtypes of melanoma in the path reports from our pathologist showed the following frequencies: superficial spreading melanoma (SSM) (52.6%), lentigo malign melanoma (LMM) (5.3%), nodular (31.6%), acral (10.5%) (Table2). In two cases this parameter was not assessed: for the patient with laser intervention of the primary tumor and for the patient diagnosed with melanoma instead of a nevus. We divided the path report errors found in our study in 4 categories: absence of histological examination, wrong histological diagnosis, incomplete path reports and delayed diagnosis (Table 3). In the majority of cases a histopathological second opinion wasn t indicated by the dermatologist or the plastic surgeon. The histopathological diagnosis was absent in three cases. Two patients had laser intervention for melanocytic lesion without dermoscopic evaluation and biopsy. One presented subsequently a recurrent lesion confirmed histologically as lentigo malign melanoma and the other patient presented multiple cutaneous metastases. The third patient had metastatic melanoma, with a brain metastasis surgically removed, but the nodular melanoma of 3/4 cm on his left deltoid area wasn t excised during this first hospitalization. In the wrong diagnosis category we included 3 cases. One patient had a paranasal tumor removed and diagnosed as papilloma instead of melanoma and had three different histological diagnoses for the lymph node metastasis in three different clinics: poorly differentiated parotid carcinoma, papillary adenocarcinoma and melanoma metastasis. The slides of the primary tumor were reviewed and the diagnosis was of nodular melanoma. The second wrong diagnosis was of a melanoma brain metastasis diagnosed as carcinoma metastasis. The third patient was histologically misdiagnosed with melanoma, instead of a benign nevus (confirmed by other two histopathologic examinations by different pathologists). The majority of patients in the incomplete path reports subgroup had no determination of the Breslow index (35.7%) or it was erroneously assessed (35.7%), making impossible to stage the tumor and establish the treatment options and prognosis of these patients. In all of these cases the doctor didn t ask or recommend for a second opinion of another pathologist, a fact that in some cases contributed to adverse clinical outcomes. For a young 30 years old female patient, with nodular melanoma and a tumor thickness of 4 mm, the histopathology report was delayed for 42 days. During this time she made several phone calls to the clinic, asking about the diagnosis, as she was very scared about it. For this lot of patients, the information provided in the pathology reports was not in accordance with the recommendations from the international consensus for melanoma (Table 4). OUTCOMES We believe it is very important to continuously try to improve the diagnosis and management of cutaneous melanoma by any means. The fact that melanoma incidence is still increasing, the young age and advanced stages that patients are diagnosed in our country, are 228 Maedica A Journal of Clinical Medicine, Volume 10 No
4 Path report error Number of patients Absence of tumor thickness (Breslow index) 5 Wrong Breslow thickness 5 Wrong histologic type 2 Absence of mitotic rate 8 Absence of ulceration status 4 Surgical margins not evaluated 4 Absence of microsatellites status 2 TABLE 4. Incomplete path reports. strong reasons for our viewpoints. In Romania, 25% of the patients present with stage III and IV disease. The difficulty that we encountered in managing these cases, the time lost for the patients, spent walking from one hospital or clinic to another and from one specialist to another, prompted us to present these errors. The number of cases we present in our study may seem small but they were selected only from one doctor s records and only the cases with complete medical documents. So we believe that the number is much higher across the country. A recent study, published in February 2015, investigated the adherence to international guidelines for the pathology reporting of melanoma in several centers from Italy. Over 600 cases were included but the information was obtained from seven cancer registries. The authors recommend a better dissemination and adoption of a standardized reporting system (27). In our country the data reported by the eight regional registries established since 2007 (28) are incomplete, making it impossible to know the real impact and characteristics of this disease in the population, essential for prevention and control. Melanoma cases are not reported separately but together with other types of skin cancers and no information from pathology reports is included. We continue with the presentation of two cases which exemplify our conclusions. Case 1: A 25 year old male patient, presented to a plastic surgeon for a bleeding, ulcerated tumor, in the left pectoral area. Excisional biopsy was performed. The path report was incomplete: no histologic subtype, Breslow thickness or mitotic rate were reported. Also no information about angiolymphatic and neural invasion, inflammatory infiltrate, regression, growth phase and microscopic satellitosis were found in this report. The Clark level of invasion was II. Six days after receiving the diagnosis he presented it to a dermatologist but no second opinion for the histologic slide was recommended. The patient went by himself for a second opinion and the diagnosis was of ulcerated nodular melanoma, with 2.89 mm thickness, Clark level IV. The sentinel lymph node biopsy was negative. Three years later he presented a lymphadenopathy in the left axilla and in transit metastasis. A complete lymph node dissection and reexcision of the primary tumor scar were carried out. The histopathological assessment confirmed the melanoma metastasis. He received adjuvant therapy with interferon. Case 2: A 54 year old female patient was diagnosed with melanoma located in the parietal left area of the scalp. The tumor was excised with 1cm surgical margins. The histopathological diagnosis was incomplete, with no histologic subtype, a Breslow index of 0,9 mm and a Clark level IV. A month later, a cutaneous metastasis appeared near the surgical scar. The diagnosis was confirmed after surgical removal. She received adjuvant therapy with interferon in low doses and chemotherapy with Dacarbazine. Our pathologist reviewed the primary tumor slides and the diagnosis was of invasive superficial spreading melanoma, ulcerated, with a 4.35 mm tumor thickness (not 0.9 mm). The patient continued the oncologic treatment. CONCLUSION Although we have a better understanding of the pathogenesis of melanoma and improved early diagnostic possibilities, the burden of disease and societal costs remain high. This article raises some current issues regarding melanoma diagnosis in our country in the 21 st century. Our study investigated the actual practice of melanoma diagnosis in Romania and presented the most frequent path report errors, with an influence on the patient outcome. A correct diagnosis starts from a complete and properly performed examination protocol. We want to emphasize the importance of a standardized histopathological evaluation of melanocytic tumors, consistent with the generally accepted standards, leading to improved healthcare quality and reduced medico legal risks associated with melanoma. Maedica A Journal of Clinical Medicine, Volume 10 No
5 Conflict of interests: none declared. Financial support: This paper is supported by the Sectorial Operational Programme Human Resources Development (SOP HRD), financed from the European Social Fund and by the Romanian Government under the contract number POSDRU/159/1.5/S/137390/ to Alina Avram. REFERENCES 1. Tronnier M, Mitteldorf C Treating advanced melanoma: current insights and opportunities. Cancer Manag Res. 2014;6: Mukherji A, Rathi AK, Mohanta PK, et al. A single institution 18-years retrospective analysis of malignant melanoma. Gulf J Oncolog. 2015;1: Bataille V Early detection of melanoma improves survival. Practitioner. 2009;253: Mervic L Prognostic factors in patients with localized primary cutaneous melanoma. Acta dermatovenerologica Alpina, Pannonica, Adriat. 2012;21: Balch CM, Gershenwald JE, Soong S-J, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27: Piris A, Mihm MC, Duncan LM AJCC melanoma staging update: Impact on dermatopathology practice and patient management. J Cutan Pathol. 2011;38: Fong ZV, Tanabe KK Comparison of melanoma guidelines in the U.S.A., Canada, Europe, Australia and New Zealand: a critical appraisal and comprehensive review. Br J Dermatol. 2014;170: Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--update Eur J Cancer. 2012;48: Garbe C, Eigentler TK, Bauer J, et al. Histopathological diagnostics of malignant melanoma in accordance with the recent AJCC classification 2009: Review of the literature and recommendations for general practice. J Dtsch Dermatol Ges. 2011;9: Carolina S, Smoller BR Protocol for the Examination of Specimens From Patients With Melanoma of the Skin. 2012;(June) 11. Scolyer RA, Judge MJ, Evans A, et al. Data set for pathology reporting of cutaneous invasive melanoma: recommendations from the international collaboration on cancer reporting (ICCR). Am J Surg Pathol. 2013;37: Document C, Cancer A, Manual S Primary Cutaneous Melanoma Structured.; Wellington: Sydney and New Zealand Guidelines Group. Australian Cancer Network Melanoma Guidelines Revision Working Party Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand: Cancer Council Australia and Australian Cancer Network.; Breslow A Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172: Murali R, Haydu LE, Long G V, et al. Clinical and pathologic factors associated with distant metastasis and survival in patients with thin primary cutaneous melanoma. Ann Surg Oncol. 2012;19: Fernandez-Flores A Prognostic factors for melanoma progression and metastasis: from Hematoxylin-Eosin to genetics. Rom J Morphol Embryol. 2012;53: Ivan D, Prieto VG An update on reporting histopathologic prognostic factors in melanoma. Arch Pathol Lab Med. 2011;135: Phan GQ, Messina JL, Sondak VK, et al. Sentinel lymph node biopsy for melanoma: indications and rationale. Cancer Control. 2009;16: Yamamoto M, Fisher KJ, Wong JY, et al. Sentinel lymph node biopsy is indicated for patients with thick clinically lymph node-negative melanoma. Cancer 2015;121: Wong SL, Balch CM, Hurley P, et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol. 2012;30: Johnson TM, Sondak VK, Bichakjian CK, et al. The role of sentinel lymph node biopsy for melanoma: evidence assessment. J Am Acad Dermatol. 2006;54: Donizy P, Kaczorowski M, Leskiewicz M, et al. Mitotic rate is a more reliable unfavorable prognosticator than ulceration for early cutaneous melanoma: a 5-year survival analysis. Oncol Rep. 2014;32: Thompson JF, Soong S-J, Balch CM, et al. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol. 2011;29: Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27: Hieken TJ, Grotz TE, Comfere NI, et al. The effect of the AJCC 7th edition change in T1 melanoma substaging on national utilization and outcomes of sentinel lymph node biopsy for thin melanoma. Melanoma Res. 2015;25: Mandalà M, Massi D Tissue prognostic biomarkers in primary cutaneous melanoma. Virchows Arch. 2014;464: Tumino R, Minicozzi P, Frasca G, et al. Population-based method for investigating adherence to international recommendations for pathology reporting of primary cutaneous melanoma: Results of a EUROCARE-5 high resolution study. Cancer Epidemiol. 2015; 39: ordin 2027/ms/ Monit Of. 2007;(822). 230 Maedica A Journal of Clinical Medicine, Volume 10 No
Talk to Your Doctor. Fact Sheet
Talk to Your Doctor Hearing the words you have skin cancer is overwhelming and would leave anyone with a lot of questions. If you have been diagnosed with Stage I or II cutaneous melanoma with no apparent
More informationDisclosures. SLNB for Melanoma 25/02/2014 SENTINEL LYMPH NODE BIOPSY FOR MELANOMA: CURRENT GUIDELINES AND THEIR CLINICAL APPLICATION
8 th Canadian Melanoma Conference February 22, 2014 Rimrock Resort Hotel, Banff, Alberta SENTINEL LYMPH NODE BIOPSY FOR MELANOMA: CURRENT GUIDELINES AND THEIR CLINICAL APPLICATION Christopher Bichakjian,
More informationMelanoma Underwriting Presented at 2018 AHOU Conference. Hank George FALU
Melanoma Underwriting Presented at 2018 AHOU Conference Hank George FALU MELANOMA EPIDEMIOLOGY 70-80,000 American cases annually Majority are in situ or thin > 20% are diagnosed age 45 8-9,000 melanoma
More informationWHAT DOES THE PATHOLOGY REPORT MEAN?
Melanoma WHAT IS MELANOMA? Melanoma is a type of cancer that affects cells called melanocytes. These cells are found mainly in skin but also in the lining of other areas such as nose and rectum, and also
More informationRebecca Vogel, PGY-4 March 5, 2012
Rebecca Vogel, PGY-4 March 5, 2012 Historical Perspective Changes In The Staging System Studies That Started The Talk Where We Go From Here Cutaneous melanoma has become an increasingly growing problem,
More informationPatient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival
MOLECULAR AND CLINICAL ONCOLOGY 7: 1083-1088, 2017 Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival FARUK TAS
More informationProtocol applies to melanoma of cutaneous surfaces only.
Melanoma of the Skin Protocol applies to melanoma of cutaneous surfaces only. Procedures Biopsy (No Accompanying Checklist) Excision Re-excision Protocol revision date: January 2005 Based on AJCC/UICC
More informationCase Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors
CASE SCENARIO 1 9/10/13 HISTORY: Patient is a 67-year-old white male and presents with lesion located 4-5cm above his right ear. The lesion has been present for years. No lymphadenopathy. 9/10/13 anterior
More informationUpdates on Melanoma: Are You Following the Latest Guidelines of Care? Jerry Brewer, MD
Updates on Melanoma: Are You Following the Latest Guidelines of Care? Jerry Brewer, MD Disclosure Statement Update on Melanoma Are You Following the Latest Guidelines of Care? I, Jerry D. Brewer, MD, do
More informationTranslating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy
American Academy of Dermatology 2018 Annual Meeting San Diego, CA, February 17, 2018 Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy Christopher Bichakjian,
More informationMalignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases
Malignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases Faruk Tas, Sidika Kurul, Hakan Camlica and Erkan Topuz Institute of Oncology, Istanbul University, Istanbul, Turkey Received
More informationMalignant tumors of melanocytes : Part 3. Deba P Sarma, MD., Omaha
Malignant tumors of melanocytes : Part 3 Deba P Sarma, MD., Omaha Let s go over one case of melanoma using the following worksheet. Of the various essential information that needs to be included in the
More informationMichael T. Tetzlaff MD, PhD
Update on American Joint Cancer Committee (AJCC) staging system for primary cutaneous melanoma Emphasis on concise and accurate reporting of primary and metastatic melanoma for effective risk stratification
More informationMelanoma Update: 8th Edition of AJCC Staging System
Melanoma Update: 8th Edition of AJCC Staging System Rosalie Elenitsas, M.D. Professor of Dermatology Director, Dermatopathology University of Pennsylvania DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY None
More informationMelanoma-Back to Basics I Thought I Knew Ya! Paul K. Shitabata, M.D. Dermatopathologist APMG
Melanoma-Back to Basics I Thought I Knew Ya! Paul K. Shitabata, M.D. Dermatopathologist APMG At tumor board, a surgeon insists that all level II melanomas are invasive since they have broken through the
More informationQuality ID #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination
Quality ID #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY MEASURE TYPE: Outcome DESCRIPTION: Pathology
More informationMeasure #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination
Measure #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Outcome DESCRIPTION: Pathology reports
More informationGenetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology
Genetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology Outline Germline testing CDKN2A BRCA2 BAP1 Somatic testing Gene expression profiling (GEP) BRAF Germline vs Somatic testing
More informationDesmoplastic Melanoma: Clinical Behavior and Management Implications
Desmoplastic Melanoma: Clinical Behavior and Management Implications Collier S. Pace, MD, a Jyoti P. Kapil, MD, b Luke G. Wolfe, MS, c Brian J. Kaplan, MD, c and James P. Neifeld, MD c a Division of Plastic
More informationImpact of Prognostic Factors
Melanoma Prognostic Factors: where we started, where are we going? Impact of Prognostic Factors Staging Management Surgical intervention Adjuvant treatment Suraj Venna, MD Assistant Clinical Professor,
More informationCutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma. Cutaneous Melanoma: Epidemiology (USA)
The Sentinel Node in Head and Neck Melanoma Cutaneous Melanoma: Epidemiology (USA) 6 th leading cause of cancer among men and women 68,720 new cases of invasive melanoma in 2009 8,650 deaths from melanoma
More informationUpdate on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma. Michael T. Tetzlaff MD, PhD
Update on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma Michael T. Tetzlaff MD, PhD Associate Professor Departments of Pathology (Dermatopathology) and Translational and Molecular Pathology
More informationPrimary Cutaneous Melanoma Pathology Reporting Proforma DD MM YYYY. *Tumour site. *Specimen laterality. *Specimen type
Primary Cutaneous Melanoma Pathology Reporting Proforma Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth DD MM YYYY Sex Male Female
More informationClinico-pathological Features of Patients with Melanoma and Positive Sentinel Lymph Node Biopsy: A Single Institution Experience
2015;23(2):122-129 CLINICAL ARTICLE Clinico-pathological Features of Patients with Melanoma and Positive Sentinel Lymph Node Biopsy: A Single Institution Experience Damir Homolak 1, Mirna Šitum 2,3, Hrvoje
More information1
www.clinicaloncology.com.ua 1 Prognostic factors of appearing micrometastases in sentinel lymph nodes in skin melanoma M.N.Kukushkina, S.I.Korovin, O.I.Solodyannikova, G.G.Sukach, A.Yu.Palivets, A.N.Potorocha,
More informationEpithelial Cancer- NMSC & Melanoma
Epithelial Cancer- NMSC & Melanoma David Chin MB, BCh, BAO, LRCP, LRCS (Ireland) MCh(MD), PhD (UQ), FRCS, FRACS (Plast) Plastic & Reconstructive Surgeon Visiting Scientist Melanoma Genomic Group & Drug
More informationBreslow Thickness and Clark Level Evaluation in Albanian Cutaneous Melanoma
Research DOI: 10.6003/jtad.16104a2 Breslow Thickness and Clark Level Evaluation in Albanian Cutaneous Melanoma Daniela Xhemalaj, MD, Mehdi Alimehmeti, MD, Susan Oupadia, MD, Majlinda Ikonomi, MD, Leart
More informationMichael T. Tetzlaff MD, PhD
American Joint Cancer Committee (AJCC) staging system for primary cutaneous melanoma (8 th Edition) and principles of sentinel lymph node evaluation Emphasis on concise and accurate reporting of primary
More informationPublished Ahead of Print on December 14, 2009 as /JCO J Clin Oncol by American Society of Clinical Oncology
Published Ahead of Print on December 14, 2009 as 10.1200/JCO.2009.24.7734 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2009.24.7734 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L
More informationPredictive Factors for the Positivity of the Sentinel Lymph Node in Malignant Melanoma
ORIGINAL RESEARCH SURGERY // ANATOMO-PATHOLOGY Predictive Factors for the Positivity of the Sentinel Lymph Node in Malignant Melanoma Călin Crăciun, Orsolya Hankó- Bauer, Zalán Benedek, Sorin Sorlea, Marius
More informationDr. Brent Doolan, BSc MBBS MPH
Impact of partial biopsies on the need for complete excisional surgery in the management of cutaneous melanomas: A multi-centre review Dr. Brent Doolan, BSc MBBS MPH Peter MacCallum Cancer Centre, Melbourne
More informationContrast with Australian Guidelines A/Pr Pascale Guitera,
Contrast with Australian Guidelines A/Pr Pascale Guitera, Dermatologist, Sydney University NO CONFLICT OF INTEREST Sydney Melanoma Diagnostic Centre, RPAH 2011 2008 225 pages 16 pages http://www.cancer.org.au/file/healthprofessionals/clinica
More informationAJCC 8 Implementation January 1, 2018 Melanoma of the Skin. Suraj Venna
AJCC 8 Implementation January 1, 2018 Melanoma of the Skin Suraj Venna Personalized Medicine AJCC 8 th Edition This Time It s Personal Traditional AJCC (TNM) population-based analyses of large databases
More informationDENOMINATOR: All melanoma pathology reports for primary malignant cutaneous melanoma
Quality ID #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination Meaningful Measure Area: Transfer of Health Information and Interoperability 2019 COLLECTION TYPE:
More informationDesmoplastic Melanoma: Surgical Management and Adjuvant Therapy
Desmoplastic Melanoma: Surgical Management and Adjuvant Therapy Dale Han, MD Assistant Professor Department of Surgery Section of Surgical Oncology No disclosures Background Desmoplastic melanoma (DM)
More informationSentinel Node Alphabet Soup: MSLT-1, DeCOG-SLT, MSLT-2, UNC
Sentinel Node Alphabet Soup: MSLT-1, DeCOG-SLT, MSLT-2, UNC David W. Ollila MD James and Jesse Millis Professor of Surgery University of North Carolina, Chapel Hill Disclosures: None July 15, 2018 AJCC
More informationCitation for published version (APA): Niebling, M. G-J. (2014). Improving Staging Accuracy in Melanoma Groningen: s.n.
University of Groningen Improving Staging Accuracy in Melanoma Niebling, Maarten Gert-Jan IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it.
More informationDavid B. Troxel, MD. Common Medicolegal Situations: Misdiagnosis of Melanoma
Common Medicolegal Situations: Misdiagnosis of Melanoma David B. Troxel, MD Medical Director, The Doctors Company, Napa, California Clinical Professor Emeritus, University of California at Berkeley Past
More informationPolypoid Melanoma, A Virulent Variant of the Nodular Growth Pattern
Polypoid Melanoma, A Virulent Variant of the Nodular Growth Pattern ELIZABETH A. MANCI, M.D., CHARLES M. BALCH, M.D..TARIQ M. MURAD, M.D., PH.D., AND SENG/JAW SOONG, PH.D. Manci, Elizabeth A., Balch, Charles
More informationPrognosis of Sentinel Node Staged Patients with Primary Cutaneous Melanoma
Prognosis of Sentinel Node Staged Patients with Primary Cutaneous Melanoma Otmar Elsaeßer 1., Ulrike Leiter 1 *., Petra G. Buettner 2, Thomas K. Eigentler 1, Friedegund Meier 1, Benjamin Weide 1, Gisela
More informationSkin lesions suspicious for melanoma: New Zealand excision margin guidelines in practice
Skin lesions suspicious for melanoma: excision margin guidelines in practice Tess Brian MBBS; 1 Michael B. Jameson MBChB, FRACP, FRCP, PhD 2,3 1 Department of Plastic and Reconstructive Surgery, Waikato
More informationORIGINAL ARTICLE. Clinical Node-Negative Thick Melanoma
ORIGINAL ARTICLE Clinical Node-Negative Thick Melanoma George I. Salti, MD; Ashwin Kansagra, MD; Michael A. Warso, MD; Salve G. Ronan, MD ; Tapas K. Das Gupta, MD, PhD, DSc Background: Patients with T4
More informationAn Overview of Melanoma. Harriet Kluger, M.D. Associate Professor Section of Medical Oncology Yale Cancer Center
An Overview of Melanoma Harriet Kluger, M.D. Associate Professor Section of Medical Oncology Yale Cancer Center Melanoma Statistics Median age at presentation 45-55 55 years Incidence: 2003 54,200 cases
More informationMorphological characteristics of the primary tumor and micrometastases in sentinel lymph nodes as a predictor of melanoma progression
Morphological characteristics of the primary tumor and micrometastases in sentinel lymph nodes as a predictor of melanoma progression M.N. Kukushkina, S.I. Korovin, O.I. Solodyannikova, G.G. Sukach, A.Yu.
More informationClinical Pathological Conference. Malignant Melanoma of the Vulva
Clinical Pathological Conference Malignant Melanoma of the Vulva History F/48 Chinese Married Para 1 Presented in September 2004 Vulval mass for 2 months Associated with watery and blood stained discharge
More informationSurgery for Melanoma and What s on the Horizon
and What s on the Horizon Giorgos C. Karakousis, M.D. Assistant Professor of Surgery Perelman School of Medicine at the University of Pennsylvania Background/Overview 76,870 cases of melanoma estimated
More informationPrecision Surgery for Melanoma
Precision Surgery for Melanoma Giorgos C. Karakousis, M.D. Assistant Professor of Surgery Perelman School of Medicine at the University of Pennsylvania Background 87,110 cases of melanoma estimated in
More informationSkin Malignancies Non - Melanoma & Melanoma Marilyn Ng, MD Dept. of Surgery M&M Conference Downstate Medical Center July 19, 2012
Skin Malignancies Non - Melanoma & Melanoma Marilyn Ng, MD Dept. of Surgery M&M Conference Downstate Medical Center July 19, 2012 Case Presentation 57 yo man with 3 month hx of a nonhealing < 1 cm right
More information> 6000 Mutations in Melanoma. Tests That Cay Be Employed. FISH for Additions/Deletions. Comparative Genomic Hybridization
Winter Clinical 2017: The Assessment and Diagnosis of Melanoma Whitney A. High, MD, JD, MEng Associate Professor, Dermatology & Pathology Director of Dermatopathology (Dermatology) University of Colorado
More informationA PRACTICAL APPROACH TO ATYPICAL MELANOCYTIC LESIONS BIJAN HAGHIGHI M.D, DIRECTOR OF DERMATOPATHOLOGY, ST. JOSEPH HOSPITAL
A PRACTICAL APPROACH TO ATYPICAL MELANOCYTIC LESIONS BIJAN HAGHIGHI M.D, DIRECTOR OF DERMATOPATHOLOGY, ST. JOSEPH HOSPITAL OBJECTIVES Discuss current trends and changing concepts in our understanding of
More informationThin Melanoma. N Context. The incidence of malignant melanoma is
Thin Melanoma David E. Elder, MB ChB, FRCPA N Context. The incidence of malignant melanoma is increasing and a preponderance of the melanomas diagnosed today are thin in terms of Breslow criteria. Although
More informationMelanoma Quality Reporting
Melanoma Quality Reporting September 1, 2013 December 31, 2016 Laurence McCahill, MD Surgical Oncologist Metro Health Surgical Oncology Metro Health Professional Building 2122 Health Drive SW Wyoming,
More informationKatsuhiro Yamada, Natsuko Noguti, Masaaki Tsuda, Hazime Nagato, Naoko Hasunuma, Yoshihiro Umebayashi and Motomu Manabe
Akita J Med 36 : 45-52, 2009 45 Katsuhiro Yamada, Natsuko Noguti, Masaaki Tsuda, Hazime Nagato, Naoko Hasunuma, Yoshihiro Umebayashi and Motomu Manabe (Received 22 December 2008, Accepted 15 January 2009)
More information6/22/2015. Original Paradigm. Correlating Histology and Molecular Findings in Melanocytic Neoplasms
6 Correlating Histology and Molecular Findings in Melanocytic Neoplasms Pedram Gerami MD, Associate Professor of Dermatology and Pediatrics at Northwestern University Disclosures: I have been a consultant
More informationMelanoma and Dermoscopy. Disclosure Statement: ABCDE's of melanoma. Co-President, Usatine Media
Melanoma and Dermoscopy Richard P. Usatine, MD, FAAFP Professor, Family and Community Medicine Professor, Dermatology and Cutaneous Surgery Medical Director, University Skin Clinic University of Texas
More informationJohan Lyth, J Hansson, C Ingvar, E Mansson-Brahme, P Naredi, U Stierner, G Wagenius and C Lindholm. Linköping University Post Print
Prognostic subclassifications of T1 cutaneous melanomas based on ulceration, tumour thickness and Clark s level of invasion: results of a population-based study from the Swedish Melanoma Register Johan
More informationUniversity of Groningen
University of Groningen Nodular Histologic Subtype and Ulceration are Tumor Factors Associated with High Risk of Recurrence in Sentinel Node-Negative Melanoma Patients Faut, Marloes; Wevers, Kevin; van
More informationInteresting Case Series. Desmoplastic Melanoma
Interesting Case Series Desmoplastic Melanoma Anthony Maurice Kordahi, MD, Joshua B. Elston, MD, Ellen M. Robertson, MD, and C. Wayne Cruse, MD Division of Plastic Surgery, Department of Surgery, University
More informationAmelanotic melanoma of the skin detailed review of the problem
of the skin detailed review of the problem Strahil Strashilov 1, Veselin Kirov 2, Angel Yordanov 3, Yoana Simeonova 4 and Miroslava Mihailova 5 1. Department of Plastic Restorative, Reconstructive and
More informationVernon K. Sondak. Department of Cutaneous Oncology Moffitt Cancer Center Tampa, Florida
Vernon K. Sondak Department of Cutaneous Oncology Moffitt Cancer Center Tampa, Florida Australasian Melanoma Conference 2016 Sydney, NSW, Australia October 29, 2016 Disclosures Dr. Sondak is a compensated
More informationMelanoma Case Scenario 1
Melanoma Case Scenario 1 History and physical 11/5/16 Patient is a single, 48-year-old male in good health who presented to his primary physician for a yearly physical exam during which a 3.4 x 2.8 x 1.5
More informationFor additional information on meeting the criteria for Mohs, see Appendix 2.
Position Statement on Appropriate Uses of Paraffin Sections in Association (Approved by the Board of Directors: August 1, 2011; Revised November 5, 2011; Revised August 9, 2014) According to AMA/CPT, Mohs
More informationEpidemiology. Objectives 8/28/2017
Case based Discussion of Head and Neck Melanoma: Review of Epidemiology, Risk Factors, Identification, Treatments and Prevention Jacqueline M. Doucette MS FNP-C Objectives Define and identify melanoma
More informationMelanoma Case Scenario 1
Melanoma Case Scenario 1 History and physical 11/5/16 Patient is a single, 48-year-old male in good health who presented to his primary physician for a yearly physical exam during which a 3.4 x 2.8 x 1.5
More informationNAACCR Webinar Series 1
Collecting Cancer Data: Melanoma 2013 2014 NAACCR Webinar Series April 3, 2014 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationTopics for Discussion. Malignant Melanoma. Surgical Treatment. Current Treatment of Cutaneous Melanoma 5/17/2013. Lymph Regional nodes:
Topics for Discussion What is a sentinel lymph node (SLN)? Utility of sentinel lymph biopsies: therapeutic or staging? Current Treatment of Cutaneous Melanoma Carlos Corvera, M.D. Associate Professor of
More informationDermatopathology. Dr. Rafael Botella Estrada. Hospital La Fe de Valencia
Dermatopathology Dr. Rafael Botella Estrada. Hospital La Fe de Valencia Melanoma and mimics Dr. Martin Mihm Malignant lesions result from the accumulation of mutations Class I lesions (benign) Class II
More informationAdvances in Surgical Management of Primary Melanoma: Identifying Patients Who Need More than Conventional Wide Local Excision
Advances in Surgical Management of Primary Melanoma: Identifying Patients Who Need More than Conventional Wide Local Excision Christopher J. Miller, MD Director of Penn Dermatology Oncology Center Associate
More informationMelanoma of the Skin INTRODUCTION SUMMARY OF CHANGES
24 Melanoma of the Skin C44.0 Skin of lip, NOS C44.1 Eyelid C44.2 External ear C44.3 Skin of other and unspecified parts of face C44.4 Skin of scalp and neck C44.5 Skin of trunk C44.6 Skin of upper limb
More informationSpringer Healthcare. Staging and Diagnosing Cutaneous Melanoma. Concise Reference. Dirk Schadendorf, Corinna Kochs, Elisabeth Livingstone
Concise Reference Staging and Diagnosing Cutaneous Melanoma Dirk Schadendorf, Corinna Kochs, Elisabeth Livingstone Extracted from Handbook of Cutaneous Melanoma: A Guide to Diagnosis and Treatment Published
More informationProblems in staging breast carcinoma
Problems in staging breast carcinoma Primary systemic therapy (PST) of breast carcinoma pathologists tasks Dr. Janina Kulka, 2nd Department of Pathology, Semmelweis University Budapest Austro-Hungarian
More informationORIGINAL ARTICLE Cutaneous malignant melanoma: clinical and histopathological review of cases in a Malaysian tertiary referral centre
Malaysian J Pathol 202; (2) : 97 0 ORIGINAL ARTICLE Cutaneous malignant melanoma: clinical and histopathological review of cases in a Malaysian tertiary referral centre Jayalakshmi PAILOOR, Kein-Seong
More informationIs There a Benefit to Sentinel Lymph Node Biopsy in Patients With T4 Melanoma?
Is There a Benefit to Sentinel Lymph Node Biopsy in atients With T4 Melanoma? Csaba Gajdos, MD 1 ; Kent A. Griffith, MH, MS 2 ; Sandra L. Wong, MD 1 ; Timothy M. Johnson, MD 1,3 ; Alfred E. Chang, MD 1
More informationMelanoma of the Skin
24 Melanoma of the Skin C44.0 Skin of lip, NOS C44.1 Eyelid C44.2 External ear C44.3 Skin of other and unspecified parts of face C44.4 Skin of scalp and neck C44.5 Skin of trunk C44. Skin of upper limb
More informationTumor Mitotic Rate Added to the Equation: Melanoma Prognostic Factors Changed?
Ann Surg Oncol (2015) 22:2978 2987 DOI 10.1245/s10434-014-4349-3 ORIGINAL ARTICLE MELANOMAS Tumor Mitotic Rate Added to the Equation: Melanoma Prognostic Factors Changed? A Single-Institution Database
More informationTracking skin cancers and melanoma at the microscopic level
Tracking skin cancers and melanoma at the microscopic level Rosalie Elenitsas, M.D. Professor of Dermatology Director of Dermatopathology Hospital of the University of Pennsylvania May 12, 2017 Outline
More informationPoor Outcomes in Head and Neck Non-Melanoma Cutaneous Carcinomas
10 The Open Otorhinolaryngology Journal, 2011, 5, 10-14 Open Access Poor Outcomes in Head and Neck Non-Melanoma Cutaneous Carcinomas Kevin C. Huoh and Steven J. Wang * Head and Neck Surgery and Oncology,
More informationHistotechnological problems in dermatopathology and their possible consequences
Histotechnological problems in dermatopathology and their possible consequences Zsolt B. Argenyi, M.D. Professor of Pathology & Dermatology Director of Dermatopathology University of Washington, Seattle,
More information1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter.
Skin Cancer follow up guidelines If NEW serious diagnosis given: 1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter. 2. Free prescription information details. 3.
More informationMetastatic Melanoma. Cynthia Kwong February 16, 2017 SUNY Downstate Medical Center Department of Surgery Grand Rounds
Metastatic Melanoma Cynthia Kwong February 16, 2017 SUNY Downstate Medical Center Department of Surgery Grand Rounds Case Presentation 77 year old male with previous history of scalp melanoma and thyroid
More informationToby Maurer, MD University of California, San Francisco. Lifetime risk of an American developing melanoma
Distinguishing Pigmented Skin Lesions and Melanoma Toby Maurer, MD University of California, San Francisco Epidemiology of Melanoma Lifetime risk of an American developing melanoma 1935: 1 in 1500 1980:
More informationToby Maurer, MD University of California, San Francisco. Lifetime risk of an American developing melanoma
Distinguishing Pigmented Skin Lesions and Melanoma Toby Maurer, MD University of California, San Francisco Epidemiology of Melanoma Lifetime risk of an American developing melanoma 1935: 1 in 1500 1980:
More informationWHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER?
CANCER STAGING TNM and prognosis in CRC WHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER? Alessandro Lugli, MD Institute of Pathology University of Bern Switzerland Maastricht, June 19
More informationMalignant Melanoma Early Stage. A guide for patients
This melanoma patient brochure is designed to help educate melanoma patients and their caregivers. It was developed under the guidance of Dr. Michael Smylie, Professor, Department of Oncology, University
More informationApoptosis in cutaneous melanomas
Romanian Journal of Morphology and Embryology 2007, 48(4):343 347 ORIGINAL PAPER Apoptosis in cutaneous melanomas MARIANA COSTACHE 1), OLGA SIMIONESCU 2), MARIA SAJIN 3), ALINA CHEFANI 4), ANA MARIA ENE
More informationWorld Articles of Ear, Nose and Throat Page 1
World Articles of Ear, Nose and Throat ---------------------Page 1 Primary Malignant Melanoma of the Tongue: A Case Report Authors: Nanayakkara PR*, Arudchelvam JD** Ariyaratne JC*, Mendis K*, Jayasekera
More informationWhat are the new AJCC Staging System changes, and how will they affect my patients?
What are the new AJCC Staging System changes, and how will they affect my patients? Emily Y. Chu, M.D., Ph.D. Assistant Professor of Dermatology & Pathology and Laboratory Medicine University of Pennsylvania
More informationIdentifying Skin Cancer. Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018
Identifying Skin Cancer Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018 American Cancer Society web site Skin Cancer Melanoma Non-Melanoma
More informationMelanoma Surgery Update James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division
Melanoma Surgery Update 2018 James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division Surgery for Melanoma Mainstay of treatment for potentially
More informationSurgical Issues in Melanoma
Surgical Issues in Melanoma Mark B. Faries, MD, FACS Director, Donald L. Morton Melanoma Research Program Director, Surgical Oncology Training Program Professor of Surgery John Wayne Cancer Institute Surgical
More informationTherapeutic Lymph Node Dissection in Melanoma: Different Prognosis for Different Macrometastasis Sites?
Ann Surg Oncol (01) 19:91 91 DOI.14/s44-01-401- ORIGINAL ARTICLE MELANOMAS Therapeutic Lymph Node Dissection in Melanoma: Different Prognosis for Different Macrometastasis Sites? K. P. Wevers, MD, E. Bastiaannet,
More informationPage 1 of 3. We suggest the following changes:
Page 1 of 3 Loren E. Clarke, M.D. Myriad Genetic Laboratories, Inc. 320 Wakara Way, Salt Lake City, UT 84108 Phone: 801.883.3470 Email: lclarke@myriad.com Date of Request: June 2017 NCCN Guidelines Panel:
More informationNodal Treatment in Melanoma: Snow to MSLT-II
Nodal Treatment in Melanoma: Snow to MSLT-II Mark B. Faries, MD, FACS Director, Donald L. Morton Melanoma Research Program Program Director, JWCI Complex General Surgical Oncology Fellowship Director,
More informationProposal for a 2-stage RCT in high risk primary SCC: COMMISSAR Catherine Harwood Barts Health NHS Trust / QMUL
Proposal for a 2-stage RCT in high risk primary SCC: COMMISSAR Catherine Harwood Barts Health NHS Trust / QMUL on behalf of Dr Louise Lansbury, Prof Fiona Bath-Hextall Nottingham Centre for Evidence Based
More informationMultispectral Digital Skin Lesion Analysis. Summary
Subject: Multispectral Digital Skin Lesion Analysis Page: 1 of 8 Last Review Status/Date: March 2016 Multispectral Digital Skin Lesion Analysis Summary There is interest in noninvasive devices that will
More information47. Melanoma of the Skin
1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting
More informationReport Back 12 th Canadian Melanoma Conference February 22 24, 2018
1 Report Back 12 th Canadian Melanoma Conference February 22 24, 2018 2 Below is a report back of major themes gleaned from the 12 th Annual Canadian Melanoma Conference along with some photos, anecdotes,
More informationDesmoplastic Melanoma R/O BCC. Clinical Information. 74 y.o. man with lesion on left side of neck r/o BCC
R/O BCC Sabine Kohler, M.D. Professor of Pathology and Dermatology Dermatopathology Service Stanford University School of Medicine Clinical Information 74 y.o. man with lesion on left side of neck r/o
More informationResearch Article Prediction of Sentinel Node Status and Clinical Outcome in a Melanoma Centre
Skin Cancer Volume 2013, Article ID 904701, 7 pages http://dx.doi.org/10.1155/2013/904701 Research Article Prediction of Sentinel Node Status and Clinical Outcome in a Melanoma Centre Vera Teixeira, 1
More information